(451 days)
Not Found
No
The device description and performance studies indicate a standard immunoassay test, with no mention of AI or ML technologies.
No.
The device is a diagnostic test for pregnancy, not a device intended for treating or preventing disease.
Yes
The device detects human chorionic gonadotropin in urine or serum to aid in the early detection of pregnancy, which is a diagnostic purpose.
No
The device description clearly indicates it is a "rapid chromatographic immunoassay" and a "single cassette device," which are physical components, not software.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use explicitly states it's for the "qualitative detection of human chorionic gonadotropin in urine or serum to aid in the early detection of pregnancy." This involves testing biological samples (urine or serum) in vitro (outside the body) to provide diagnostic information.
- Device Description: The description confirms it "measures the presence of the hormone Human Chorionic Gonadotrophin (HCG) in human urine or serum." This further reinforces the in vitro testing of biological samples.
- Testing Method: It's described as a "rapid chromatographic immunoassay," which is a common method used in IVD tests to detect specific substances in biological fluids.
The definition of an In Vitro Diagnostic (IVD) device is a medical device intended for use in vitro for the examination of specimens, including blood and tissue donations, derived from the human body, solely or principally for the purpose of providing information concerning a physiological or pathological state, or concerning a congenital abnormality, or to determine the safety and compatibility with potential recipients, or to monitor therapeutic measures.
This device clearly fits this definition.
N/A
Intended Use / Indications for Use
The Altest Pregnancy Rapid Combo Test Cassette is a rapid chromatographic immunoassay for the qualitative detection of human chorionic gonadotropin in urine or serum to aid in the early detection of pregnancy. The test is for health care professionals use including professionals at point of care (POC).
Used in the 510(k) Summary:
The Alltest Pregnancy Rapid Combo Test Cassette is a rapid chromatographic immunoassay for the qualitative detection of human chorionic gonadotropin in urine or serum to aid in the early detection of pregnancy.
The test is for health care professionals use including professionals at point of care (POC).
Product codes (comma separated list FDA assigned to the subject device)
JHI
Device Description
The Alltest Pregnancy Rapid Combo Test Cassette measures the presence of the hormone Human Chorionic Gonadotrophin (HCG) in human urine or serum for the early detection of pregnancy. During pregnancy, HCG is produced by the placenta shortly after the embryo attaches to the uterine lining. The test device is used as a single cassette device.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
health care professionals use including professionals at point of care (POC).
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Analytical Performance studies included Precision/Reproducibility/Cut-Off Value, Stability, Specificity/Cross Reactivity (High Dose Effect, Effects of hCG ß-core fragment, Effects of glycoprotein LH, FSH and TSH), and Interference.
Comparison Studies: A method comparison study was performed, comparing the results obtained from the Alltest hCG Pregnancy Rapid Combo Test Cassette to the results from predicate devices (K132834). 105 urine and 107 serum samples were collected from 212 women (about half of them were pregnant, early stage at less than 5 weeks) from three testing sites. Samples were randomly collected at various times throughout the day. Ages ranged from 20 to 49 years. Samples were tested by different health professionals with the proposed and the predicate devices at each site. The study result shows that 100% agreement for all samples.
Clinical Studies: Not applicable
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Based on the comparison study, for urine cassette: 100% positive agreement (53/53), 100% negative agreement (52/52). For serum cassette: 100% positive agreement (58/58), 100% negative agreement (49/49).
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 862.1155 Human chorionic gonadotropin (HCG) test system.
(a)
Human chorionic gonadotropin (HCG) test system intended for the early detection of pregnancy —(1)Identification. A human chorionic gonadotropin (HCG) test system is a device intended for the early detection of pregnancy is intended to measure HCG, a placental hormone, in plasma or urine.(2)
Classification. Class II.(b)
Human chorionic gonadotropin (HCG) test system intended for any uses other than early detection of pregnancy —(1)Identification. A human chorionic goadotropin (HCG) test system is a device intended for any uses other than early detection of pregnancy (such as an aid in the diagnosis, prognosis, and management of treatment of persons with certain tumors or carcinomas) is intended to measure HCG, a placental hormone, in plasma or urine.(2)
Classification. Class III.(3)
Date PMA or notice of completion of a PDP is required. As of the enactment date of the amendments, May 28, 1976, an approval under section 515 of the act is required before the device described in paragraph (b)(1) may be commercially distributed. See § 862.3.
0
Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health and Human Services logo on the left and the FDA logo on the right. The FDA logo features the letters "FDA" in a blue square, followed by the words "U.S. Food & Drug Administration" in blue text.
January 31, 2022
Hangzhou AllTest Biotech Co., Ltd % Joe Shia Director LSI International Inc 504E Diamond Ave, Suite J Gaithersburg, Maryland 20877
Re: K203272
Trade/Device Name: Alltest Pregnancy Rapid Combo Test Cassette Regulation Number: 21 CFR 862.1155 Regulation Name: Human Chorionic Gonadotropin (HCG) Test System Regulatory Class: Class II Product Code: JHI Dated: November 1, 2021 Received: November 2, 2021
Dear Joe Shia:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
1
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801 and Part 809); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Marianela Perez-Torres, Ph.D. Deputy Director Division of Chemistry and Toxicology Devices OHT7: Office of In Vitro Diagnostics and Radiological Health Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K203272
Device Name Alltest Pregnancy Rapid Combo Test Cassette
Indications for Use (Describe)
The Altest Pregnancy Rapid Combo Test Cassette is a rapid chromatographic immunoassay for the qualitative detection of human chorionic gonadotropin in urine or serum to aid in the early detection of pregnancy. The test is for health care professionals use including professionals at point of care (POC).
Type of Use (Select one or both, as applicable)
| ☑ Prescription Use (Rx) (21 CFR 201.100(b)) | ☐ Over-The-Counter Use (21 CFR 201.66) |
|---|---|
| -------------------------------------------------------- | --------------------------------------------------- |
Prescription Use (Part 21 CFR 801 Subpart D)
__ Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
510(k) SUMMARY K203272
| 1. Date: | December 23, 2021 |
|---|---|
| 2. Submitter: | Hangzhou AllTest Biotech Co., Ltd. |
| No. 550, Yinhai Street | |
| Hangzhou, China, 310018 | |
| 3. Contact person: | Joe Shia |
| LSI International Inc. | |
| 504 East Diamond Ave., Suite I | |
| Gaithersburg, MD 20877 | |
| Telephone: 240-505-7880 | |
| Fax: 301-916-6213 | |
| Email:shiajl@yahoo.com |
-
- Device Name: Alltest Pregnancy Rapid Combo Test Cassette
Classification: ClassII
- Device Name: Alltest Pregnancy Rapid Combo Test Cassette
| Product
| Code | CFR # | Panel |
|---|---|---|
| JHI | 862.1155, Human chorionic | |
| gonadotropin (HCG) test system | Clinical Chemistry |
-
- Predicate Devices:
K132834, Clarity Diagnostics Clarity hCG Pregnancy Combo Test Cassette
- Predicate Devices:
-
- Intended Use
The Alltest Pregnancy Rapid Combo Test Cassette is a rapid chromatographic immunoassay for the qualitative detection of human chorionic gonadotropin in urine or serum to aid in the early detection of pregnancy.
- Intended Use
The test is for health care professionals use including professionals at point of care (POC).
-
- Device Description
The Alltest Pregnancy Rapid Combo Test Cassette measures the presence of the hormone Human Chorionic Gonadotrophin (HCG) in human urine or serum for the early detection of pregnancy. During pregnancy, HCG is produced by the placenta shortly after the embryo attaches to the uterine lining. The test device is used as a single cassette device.
- Device Description
-
- Substantial Equivalence Information
4
A summary comparison of features of the Alltest Pregnancy Rapid Combo Test Cassette and the predicate device is provided in the following table.
| Item | Device | Predicate |
|---|---|---|
| Intended Use | Rapid qualitative detection of | |
| hCG to aid in the early detection | ||
| of pregnancy. | Same | |
| Specimen | Urine or serum | Same |
| Principle | Lateral flow Sandwich | |
| Immunochromatographic Assay | Same | |
| Detection reagent | Colloidal gold | Same |
| Read time | Serum: 5 minutes Urine: | |
| 3 minutes | 5 minutes for both | |
| serum and urine | ||
| Usage | For prescription use | Same |
| Cut-Off Values | 10 mIU/mL for serum and 20 | |
| mIU/mL for urine | Same | |
| Configurations | Cassette | Same |
| Storage | 2 – 30°C | Same |
9. Test Principle
It is a lateral flow chromatographic immunoassay. When a sample is added, the sample is absorbed into the device by capillary action and mixes with the antibodydye conjugate (mouse anti-beta HCG monoclonal antibody), flowing across the precoated (Goat anti HCG polyclonal antibody) membrane. At analyte concentration above the target cut off, it produces a colored test line that indicates a positive result. When analyte concentration is below the cutoff, no colored band shows in the test region, indicating a negative result. No line in the "C" region indicates that the test is invalid.
10. Performance Characteristics
Analytical Performance
- a. Precision/Reproducibility/Cut-Off Value
Negative serum or urine specimens were spiked with varying hCG (commercially available and traceable to the 5th WHO international Standard) concentrations. The spiked samples were measured in 6 replicates each day for 5 days using 3 different lots at three testing sites. Tests were performed by six different operators for each sample concentration. Results are shown in the following tables.
| hCG
Concentration | Site 1
Lot 2 | Site 2
Lot 3 | Site 3
Lot 1 | Total
result | %
Negative | %
Positive |
| ---------------------- | ----------------- | ----------------- | ----------------- | ----------------- | --------------- | --------------- |
|---|
Serum
5
| (mIU/mL) | - | + | - | + | - | + | - | + | - | + |
|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 30 | 0 | 30 | 0 | 30 | 0 | 90 | 0 | 100 | 0 |
| 3 | 30 | 0 | 30 | 0 | 30 | 0 | 90 | 0 | 100 | 0 |
| 5 | 30 | 0 | 30 | 0 | 30 | 0 | 90 | 0 | 100 | 0 |
| 8 | 7 | 23 | 7 | 23 | 8 | 22 | 22 | 68 | 24.4 | 75.6 |
| 10 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 90 | 0 | 100 |
| 12 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 90 | 0 | 100 |
| 15 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 90 | 0 | 100 |
| 20 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 90 | 0 | 100 |
| 50 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 90 | 0 | 100 |
Urine
| hCG
Concentration
(mIU/mL) | Site 1
Lot 2 | | Site 2
Lot 3 | | Site 3
Lot 1 | | Total
result | | %
Negative | %
Positive |
|----------------------------------|-----------------|----|-----------------|----|-----------------|----|-----------------|----|---------------|---------------|
| | - | + | - | + | - | + | - | + | | |
| 0 | 30 | 0 | 30 | 0 | 30 | 0 | 90 | 0 | 100 | 0 |
| 5 | 30 | 0 | 30 | 0 | 30 | 0 | 90 | 0 | 100 | 0 |
| 10 | 30 | 0 | 30 | 0 | 30 | 0 | 90 | 0 | 100 | 0 |
| 15 | 15 | 15 | 16 | 14 | 15 | 15 | 46 | 44 | 51.1 | 48.9 |
| 17.5 | 6 | 24 | 6 | 24 | 6 | 24 | 18 | 72 | 20 | 80 |
| 20 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 90 | 0 | 100 |
| 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 90 | 0 | 100 |
| 50 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 90 | 0 | 100 |
| 100 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 90 | 0 | 100 |
Cut-off values of 10 mIU/mL for serum and 20 mIU/mL for urine are verified.
b. Stability
Stable at 2-30°C for 24 months based on the accelerated stability study at 55°C.
c. Specificity / Cross Reactivity
High Dose Effect
Negative urine (serum) samples were spiked with varying high hCG concentrations ranging from 500 to 2,000,000 mIU/mL. The spiked samples were tested by 3 different lots and 3 different operators. No hook effect was observed at these concentrations.
Effects of hCG ß-core fragment
Negative and positive samples (5 and 10 mIU/mL hCG in serum; 10 and 20 mIU/mL hCG in urine) were spiked with various concentrations of ß -core fragment hCG (0 to 2x106pmol/L). These samples were tested by 3 different lots and 3 different operators. No difference was observed for different lots and different operators. No interference was observed for these samples for the devices except that false positive was observed above the 100 pmol/L ß -core fragment hCG.
6
Effects of glycoprotein LH, FSH and TSH
Negative and positive samples (10 and 20 mIU/mL hCG for urine, and 5 and 10 mIU/mL hCG for serum) were spiked with various concentrations of other glycoprotein hormones such as LH, FSH, and TSH. Samples were tested using three different lots by three operators. No interference was observed for these samples for the device at LH concentrations up to 500 IU/mL, FSH concentrations up to 1000 mIU/mL, and TSH concentrations up to 1000 uIU/mL.
d. Interference
To evaluate potential interference from certain exogenous compounds, each interferent was made at 100X concentrate bulk and spiked in both hCG negative (5mIU/mL for serum, 10mIU/mL for urine) and hCG positive (10mIU/mL for serum, 20mIU/mL for urine) samples. Each spiked urine sample was mixed for 5 minutes to ensure a homogeneous solution before testing. Each sample was tested using 3 different lots of the testing kit. Results are shown in the following table.
| Interferents | Concentration | Negative hCG | Positive hCG | ||||
|---|---|---|---|---|---|---|---|
| Lot1 | Lot2 | Lot3 | Lot1 | Lot2 | Lot3 | ||
| Acetaminophen | 20 mg/dl | - | - | - | + | + | + |
| Acetoacetic Acid | 2000 mg/dl | - | - | - | + | + | + |
| Ascorbic Acid | 20 mg/dl | - | - | - | + | + | + |
| Atropine | 20 mg/dl | - | - | - | + | + | + |
| Acetosalicylic Acid | 20 mg/dl | - | - | - | + | + | + |
| Albumin | 2000mg/dl | - | - | - | + | + | + |
| Bilirubin | 2mg/dl | - | - | - | + | + | + |
| Caffeine | 20 mg/dl | - | - | - | + | + | + |
| Codeine | 10mg/dl | - | - | - | + | + | + |
| Ephedrine | 20 mg/dl | - | - | - | + | + | + |
| EDTA | 80 mg/dl | - | - | - | + | + | + |
| Ethanol | 1% | - | - | - | + | + | + |
| Gentisic Acid | 20 mg/dl | - | - | - | + | + | + |
| Glucose | 2000mg/dl | - | - | - | + | + | + |
| Hemoglobin | 2000mg/dl | - | - | - | + | + | + |
| Methadone | 10mg/dl | - | - | - | + | + | + |
| Phenylpropanolamine | 20 mg/dl | - | - | - | + | + | + |
| Phenothiazine | 20 mg/dl | - | - | - | + | + | + |
| Pregnanediol | 1.5 mg/dl | - | - | - | + | + | + |
| Salicylic Acid | 20 mg/dl | - | - | - | + | + | + |
| B-hydroxybutyrate | 2000mg/dL | - | - | - | + | + | + |
| Benzoylecgonine | 10mg/dL | - | - | - | + | + | + |
| Cannabinol | 10mg/dL | - | - | - | + | + | + |
| Methanol | 10% | - | - | - | + | + | + |
7
| Estriol-17-beta | 1.4mg/dL | - | - | - | + | + | + |
|---|---|---|---|---|---|---|---|
| Thiophene | 20mg/dl | - | - | - | + | + | + |
| Ampicillin | 20mg/dl | - | - | - | + | + | + |
| Tetracycline | 20mg/dl | - | - | - | + | + | + |
| Ketone | 20mg/dl | - | - | - | + | + | + |
| Total cholesterol (serum only ) | 250mg/dl | - | - | - | + | + | + |
| Triglycerides (serum only ) | 1200mg/dl | - | - | - | + | + | + |
| High-density lipoprotein (serum only) | 70mg/dl | - | - | - | + | + | + |
All data show that there is no interference for the listed compounds at the stated concentrations.
e.Effect of Urine Specified Gravity and Urine pH
Negative and positive urine samples containing 10 and 20 mIU/mL hCG were tested at pH values from 4 to 9 or at density values ranging from 1.001 to1.035 using 3 different lots by 3 different operators. Data show that there is no interference from pH ranging from 4 to 9 and specific gravity ranging from 1.001 to 1.035 of tested urine samples.
2. Comparison Studies
A method comparison study was performed, comparing the results obtained from the Alltest hCG Pregnancy Rapid Combo Test Cassette to the results from predicate devices (K132834). 105 urine and 107 serum samples were collected from 212 women (about half of them were pregnant, early stage at less than 5 weeks) from three testing Samples were randomly collected at various times throughout the day. Ages sites. ranged from 20 to 49 years. Samples were tested by different health professionals with the proposed and the predicate devices at each site. The obtained results are shown in the following tables.
Summary Results for Urine Cassette
| New Device | Cleared device | |
|---|---|---|
| + | - | |
| + | 53 | 0 |
| - | 0 | 52 |
Summary Results for Serum Cassette
| Cleared device | + | - | |
|---|---|---|---|
| New Device | + | 58 | 0 |
| - | 0 | 49 |
The study result shows that 100% agreement for all samples.
-
- Clinical Studies
Not applicable
- Clinical Studies
11.Conclusion
8
Based on the test principle and acceptable performance characteristics including precision, cut-off, interference, specificity and method comparison of the devices, it's concluded that Alltest hCG Pregnancy Serum/Urine Combo Test Cassette is substantially equivalent to the predicate.